Novartis Hopes Lubris In-Licensing Deal Will Lead To Dry Eye Solution
ON the lookout for potential ophthalmology options despite recent setbacks in the area, Novartis has now spotted ECF843, an investigative recombinant human lubricin – or natural lubricant – for dry eye.
You may also be interested in...
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
The failure of two Phase III Fovista and Lucentis combination trials in treating wet AMD probably lifts the threat of shifts towards PDGF/VEGF combinations and thereby leaves Regeneron's Eylea sales in the clear.